Reuters logo
Shire delivers first-quarter beat with 14 pct rise in earnings
May 2, 2017 / 11:18 AM / in 7 months

Shire delivers first-quarter beat with 14 pct rise in earnings

LONDON, May 2 (Reuters) - Shire, the pharma group that bought haemophilia specialist Baxalta last year, reported a better-than-expected 14 percent rise in first-quarter earnings, helped by higher sales of rare disease drugs and demand for its new dry eye medicine.

The London-listed firm reported non-GAAP diluted earnings per ADS of $3.63, beating analyst forecasts of $3.27, according to Thomson Reuters I/B/E/S. Product sales, which were boosted by the Baxalta deal, rose 110 percent to $3.4 billion.

The company reiterated its full-year forecast given in February for product sales to rise to $14.5-14.8 billion this year and earnings per share to increase to $14.60-$15.20.

Reporting by Paul Sandle; editing by Kate Holton

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below